Alpha 2.0
Login Register
» Authors » Slawomir Poletajew

Slawomir Poletajew

Explore the profile of Slawomir Poletajew including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 87
Citations 433
Followers 0
Related Specialties
Urology
Oncology
General Medicine
Top 10 Co-Authors
Wojciech Krajewski
Piotr Radziszewski
Piotr Kryst
Romuald Zdrojowy
Andrzej Tukiendorf
Lukasz Nyk
Lukasz Nowak
Hubert Kamecki
Bartosz Dybowski
Marco Moschini
Published In
Cent European J Urol
Urol Int
World J Surg Oncol
J Clin Med
Transl Androl Urol
Affiliations
Soon will be listed here.
Recent Articles
1.
A Simple Nomogram to Predict Clinically Significant Prostate Cancer at MRI-Guided Biopsy in Patients with Mild PSA Elevation and Normal DRE
Kamecki H, Tokarczyk A, Debowska M, Bialonczyk U, Malewski W, Szostek P, et al.
Cancers (Basel) . 2025 Mar; 17(5). PMID: 40075601
Background: Evidence to help avoid unnecessary prostate biopsies is being actively pursued. Our goal was to develop and internally validate a nomogram for predicting clinically significant prostate cancer (csPC) in...
2.
Role of Systematic Biopsy in the Era of Targeted Biopsy: A Review
Malewski W, Milecki T, Tayara O, Poletajew S, Kryst P, Tokarczyk A, et al.
Curr Oncol . 2024 Sep; 31(9):5171-5194. PMID: 39330011
Prostate cancer (PCa) is a major public health issue, as the second most common cancer and the fifth leading cause of cancer-related deaths among men. Many PCa cases are indolent...
3.
Prostate-Specific Membrane Antigen Expression in Patients with Primary Prostate Cancer: Diagnostic and Prognostic Value in Positron Emission Tomography-Prostate-Specific Membrane Antigen
Tayara O, Poletajew S, Malewski W, Kunikowska J, Pelka K, Kryst P, et al.
Curr Oncol . 2024 Aug; 31(8):4165-4177. PMID: 39195294
Prostate cancer represents a significant public health challenge, with its management requiring precise diagnostic and prognostic tools. Prostate-specific membrane antigen (PSMA), a cell surface enzyme overexpressed in prostate cancer cells,...
4.
Comparison of Multiparametric MRI, [Ga]Ga-PSMA-11 PET-CT, and Clinical Nomograms for Primary T and N Staging of Intermediate-to-High-Risk Prostate Cancer
Tayara O, Pelka K, Kunikowska J, Malewski W, Sklinda K, Kamecki H, et al.
Cancers (Basel) . 2023 Dec; 15(24). PMID: 38136382
Purpose Of The Report: Although multiparametric magnetic resonance imaging (mpMRI) is commonly used for the primary staging of prostate cancer, it may miss non-enlarged metastatic lymph nodes. Positron emission tomography-computed...
5.
Quantification of Gleason Pattern 4 at MRI-Guided Biopsy to Predict Adverse Pathology at Radical Prostatectomy in Intermediate-Risk Prostate Cancer Patients
Kamecki H, Mielczarek L, Szemplinski S, Debowska M, Rajwa P, Baboudjian M, et al.
Cancers (Basel) . 2023 Nov; 15(22). PMID: 38001723
Background: Data on Gleason pattern 4 (GP4) amount in biopsy tissue is important for prostate cancer (PC) risk assessment. We aim to investigate which GP4 quantification method predicts adverse pathology...
6.
Glycosaminoglycan Replacement Therapy with Intravesical Instillations of Combined Hyaluronic Acid and Chondroitin Sulfate in Patients with Recurrent Cystitis, Post-radiation Cystitis and Bladder Pain Syndrome: A Narrative Review
Poletajew S, Brzozka M, Krajewski W, Kamecki H, Nyk L, Kryst P
Pain Ther . 2023 Nov; 13(1):1-22. PMID: 37917298
Defects in the glycosaminoglycan layer (GAG) of the bladder mucosa have been identified as a significant contributor to the pathogenesis and clinical progression of chronic inflammatory diseases of the bladder,...
7.
Patient-reported pain associated with grid-based transperineal magnetic resonance imaging (MRI)/ultrasound (US) software fusion biopsy of the prostate under local anesthesia: a multicenter experience
Szemplinski S, Kamecki H, Mokrzys M, Zawadzki M, Zagozdzon B, Debowska M, et al.
Transl Androl Urol . 2023 Sep; 12(8):1250-1258. PMID: 37680225
Background: Biopsy by transperineal (TP) approach is recommended standard for prostate cancer (PC) diagnosis. To avoid pain, patients undergoing TP biopsy may be offered sedation or general anesthesia. Our aim...
8.
Polish version of the Acute Cystitis Symptom Score for patients with acute uncomplicated cystitis
Naber K, Alidjanov J, Blicharski T, Cerska M, Gadzinski W, Kawecki J, et al.
Cent European J Urol . 2023 Jul; 76(2):144-154. PMID: 37483856
Introduction: The Acute Cystitis Symptom Score (ACSS) is a self-reporting questionnaire to evaluate the symptoms and quality of life in women with uncomplicated acute cystitis (AC). The aim of the...
9.
Predictors of Clinically Significant Prostate Cancer in Patients with PIRADS Categories 3-5 Undergoing Magnetic Resonance Imaging-Ultrasound Fusion Biopsy of the Prostate
Szemplinski S, Kamecki H, Debowska M, Zagozdzon B, Mokrzys M, Zawadzki M, et al.
J Clin Med . 2023 Jan; 12(1). PMID: 36614957
Prostate biopsy is recommended in cases of positive magnetic resonance imaging (MRI), defined as Prostate Imaging Reporting and Data System (PIRADS) category ≥ 3. However, most men with positive MRIs...
10.
Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer
Krajewski W, Aumatell J, Subiela J, Nowak L, Tukiendorf A, Moschini M, et al.
Urol Oncol . 2022 Jul; 40(11):491.e11-491.e19. PMID: 35851185
Purpose: Non-muscle-invasive bladder cancers (NMIBC) constitute 3-quarters of all primary diagnosed bladder tumors. For risk-adapted management of patients with NMIBC, different risk group systems and predictive models have been developed....